Condition

Stage IIIA Non-small Cell Lung Cancer

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 49 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials49

Recruiting1

Common interventions25

Lead sponsors shown15

Clinical trials

49 shown

Pathological Response After Neoadjuvant Treatment on NSCLCNCT05167487 · 2021-12-13

PANK-003 Cell Injection Combined With Standard Adjuvant Chemotherapy After Surgery in Patients With Stage IIIA NSCLCNCT07043907 · 2025-07-08

NOT_YET_RECRUITING

Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLCNCT05894889 · 2024-01-30

ACTIVE_NOT_RECRUITING

Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)NCT04776447 · 2021-06-16

CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung CancerNCT04062708 · 2021-03-10

ACTIVE_NOT_RECRUITING

Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung CancerNCT03916419 · 2019-06-20

Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer PatientsNCT03053856 · 2017-02-14

Safety and Efficacy of Vitamin C Infusion in Combination With Local mEHT to Treat Non Small Cell Lung CancerNCT02655913 · 2015-12-01

Hypofractionated Boost Before Chemoradiation for Patients With Stage II-III Non-small Cell Lung Cancer Unsuitable for SurgeryNCT02262325 · 2015-06-08

Palliative Care Intervention in Improving Symptom Control and Quality of Life in Patients With Stage II-IV Non-small Cell Lung Cancer and Their Family CaregiversNCT02243748 · 2015-02-05

Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung CancerNCT01958372 · 2014-08-01

Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung CancerNCT02245100 · 2014-07-22

Diffusion-weighted MRI for Individualized Radiation Therapy Planning of Lung CancerNCT02059889 · 2014-07-01

Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLCNCT02059967 · 2014-03-01

Impacts of Exercise on Prognostic Biomarkers in Lung Cancer PatientsNCT01999881 · 2013-12-01

Pulmonary Rehabilitation in Improving Lung Function in Patients With Locally Advanced Non-Small Cell Lung Cancer Undergoing ChemoradiationNCT02017925 · 2013-10-01

Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive BiomarkersNCT01935336 · 2013-09-24

Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung CancerNCT01781741 · 2013-03-06

18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis TherapyNCT01806675 · 2013-03-04

Survivorship Care Planning in Patients With Colorectal or Non-Small Cell Lung CancerNCT01741636 · 2013-01-01

Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor CareNCT01726296 · 2013-01-01

Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung CancerNCT01707823 · 2012-10-01

An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)NCT01711697 · 2012-09-04

Biomarkers in Predicting Treatment Response in Samples From Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant ChemotherapyNCT01595074 · 2012-05-01

NOT_YET_RECRUITING

Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Removed by SurgeryNCT01411098 · 2011-10-01

Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung CancerNCT01383668 · 2011-06-01

Fludeoxyglucose F 18 PET/CT Scans in Predicting Therapy Response in Patients With Stage IIIA Non-Small Cell Lung Cancer Undergoing ChemoradiationNCT01314677 · 2011-04-01

Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By SurgeryNCT01345851 · 2011-03-23

ACTIVE_NOT_RECRUITING

Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung CancerNCT01457469 · 2011-01-01

Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung CancerNCT01282333 · 2011-01-01

Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid TumorsNCT01155258 · 2010-06-01

Proton Beam Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Can Be Removed By SurgeryNCT01076231 · 2010-01-01

Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerNCT00778167 · 2008-10-01

Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III Non-Small Lung Cancer That Cannot Be Removed By SurgeryNCT00662311 · 2008-03-01

Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung CancerNCT00369551 · 2006-06-01

Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical ResectionNCT00087269 · 2004-12-01

Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung CancerNCT00093756 · 2004-09-01

EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung CancerNCT00087191 · 2004-05-01

GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid TumorsNCT00074022 · 2003-10-01

Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and NeckNCT00063895 · 2003-04-01

Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by SurgeryNCT00049543 · 2002-09-01

Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung CancerNCT00040794 · 2002-05-01

Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung CancerNCT00042835 · 2002-05-01

Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By SurgeryNCT00020709 · 2001-06-01

FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung CancerNCT00020202 · 2000-06-01

Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By SurgeryNCT00005838 · 2000-03-01

Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage IIIA Non-small Cell Lung CancerNCT00005065 · 2000-01-01

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuNCT00004074 · 1999-08-01

Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung CancerNCT00003869 · 1999-04-01

Common interventions

Leading sponsors

National Cancer Institute (NCI) 18 City of Hope Medical Center 3 Fundación GECP 2 Ohio State University Comprehensive Cancer Center 2 University of Washington 2 Virginia Commonwealth University 2 Abramson Cancer Center at Penn Medicine 1 Alliance Foundation Trials, LLC. 1 Barbara Ann Karmanos Cancer Institute 1 Clifford Hospital, Guangzhou, China 1 Emory University 1 Fox Chase Cancer Center 1 Jonsson Comprehensive Cancer Center 1 Mayo Clinic 1 Peking University 1

Trial status mix

COMPLETED28

TERMINATED8

WITHDRAWN5

ACTIVE_NOT_RECRUITING3

NOT_YET_RECRUITING2

UNKNOWN2

RECRUITING1

Phase mix

PHASE120

PHASE219

NA9

PHASE34

EARLY_PHASE12

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.